Managing Lymphoma
- 2017-03-15 - FDA Approves Merck’s Keytruda (pembrolizumab) for Classical Hodgkin Lymphoma (cHL)
- 2016-07-18 - Study: Five-Year Survival Data Suggest Brentuximab Vedotin Potentially Curative in Some Hodgkin Lymphoma Patients with Limited Treatment Options
- 2016-07-07 - Takeda Receives European Commission Approval of ADCETRIS® (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
- 2016-06-10 - New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial
- 2016-05-27 - Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
- 2016-05-24 - Vitamin A may help improve pancreatic cancer chemotherapy
- 2016-05-24 - Chemo, Radiation, Surgery Combo Boosts Survival for Pancreatic Cancer Patients with Veins Involved
- 2016-05-17 - Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1
- 2016-04-11 - Improving survival and reducing side effects in Hodgkin lymphoma
- 2015-08-17 - FDA Announces Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation